Shilpa Medicare launches breakthrough therapy lenvatinib mesylate under brand Lenshil in India MD bureau3 Feb 2020 1:22 PM IST Shilpa Medicare shall launch lenvatinib, at a breakthrough price which is over 50% lower than the existing brand available in India. Prior to the...